Where I see patients (3)
My reviews
Selected research
-
Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.
Breast cancer research : BCR
-
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.
Signal transduction and targeted therapy
-
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Clinical trials
UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations
Participant-derived models may include (but are not limited to) xenografts (PDX), organoids (PDO), and cell lines (PDCLs). These models recapitulate the biology and tissue context of the original tumors from which they are derived...
Recruiting
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called...
Month 36 is assumed to be study end. Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.
Recruiting
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastati...
To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assesse...
Recruiting
4.8